Segment and Geographic Information - Schedule of Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Revenue:
Revenue	$ 216,833	$ 101,620	$ 519,147	$ 282,345
Costs and operating expenses:
Selling and marketing expense	41,267	36,758	123,355	115,077
General and administrative expense	51,973	40,852	168,458	126,273
Research and development expense	21,624	27,644	69,739	86,807
Total costs and operating expenses	184,191	162,462	562,445	502,421
Income (Loss) from operations	32,642	(60,842)	(43,298)	(220,076)
Interest income	7,360	1,744	9,482	6,152
Interest expense	(13,507)	(13,799)	(45,497)	(36,763)
Changes in fair value of financial instruments	(2,081)	5,131	(52,285)	6,067
Other income (expense), net	(89)	37	(18,447)	(323)
Net income (loss)	24,325	(67,729)	(150,045)	(244,943)
Molecular Profiling Services
Revenue:
Revenue	207,587	93,803	484,593	254,692
Costs and operating expenses:
Cost of services	66,980	54,810	193,195	167,134
Pharma Research And Development Services
Revenue:
Revenue	9,246	7,817	34,554	27,653
Costs and operating expenses:
Cost of services	2,347	2,398	7,698	7,130
Reportable Segment
Revenue:
Revenue	216,833	101,620	519,147	282,345
Costs and operating expenses:
Selling and marketing expense	41,267	36,758	123,355	115,077
General and administrative expense	51,973	40,852	168,458	126,273
Research and development expense	21,624	27,644	69,739	86,807
Total costs and operating expenses	184,191	162,462	562,445	502,421
Income (Loss) from operations	32,642	(60,842)	(43,298)	(220,076)
Interest income	7,360	1,744	9,482	6,152
Interest expense	(13,507)	(13,799)	(45,497)	(36,763)
Changes in fair value of financial instruments	(2,081)	5,131	(52,285)	6,067
Other income (expense), net	(89)	37	(18,447)	(323)
Net income (loss)	24,325	(67,729)	(150,045)	(244,943)
Reportable Segment | Molecular Profiling Services
Revenue:
Revenue	207,587	93,803	484,593	254,692
Costs and operating expenses:
Cost of services	66,980	54,810	193,195	167,134
Reportable Segment | Pharma Research And Development Services
Revenue:
Revenue	9,246	7,817	34,554	27,653
Costs and operating expenses:
Cost of services	$ 2,347	$ 2,398	$ 7,698	$ 7,130